Background: Precise subtype classification based on underlying pathophysiology is important to prevent recurrent attack in minor stroke patients. A newly developed Atherosclerosis, Small vessel disease, Cardiac source, Others (ASCO) phenotypic classification system aims to characterize patients using different grades of evidence for stroke subtypes. However, this system has not been specifically applied to minor stroke population. In our study, the impact of using the newer ASCO criteria on minor stroke etiologies was investigated, and compared with that of Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification. Methods: Consecutive patients with minor ischemic stroke (NIHSS ≤3) were assessed and subtyped by the ASCO and TOAST systems. Stroke etiologies were presented and compared. The McNemar test and k statistic were used to analyze the difference and concordance between the 2 algorithms, respectively. Results: A total of 604 first-ever minor stroke patients were analyzed in the present study. Using TOAST classification, large artery atherosclerosis was the most frequent subtype (281, 46.5%), followed by small artery occlusion category (165, 27.3%). When ASCO was applied, 37 different profiles of stroke etiologies were identified. Using grade 1 of evidence, atherosclerosis (A1) was the most frequent subtype (308, 51.0%), followed by small vessel disease (S1, 178, 29.5%). Under consideration of grades 1 and 2, 239 (39.6%) patients were classified into more than 1 category. The ASCO system revealed determined etiologies in 104 of the 137 patients classified to cause undetermined subtype by TOAST classification. Good to very good accordance was observed between ASCO grade 1 and TOAST schemes across etiologic subtypes (κ = 0.719–0.832) except cause undetermined category (κ = 0.470). Conclusion: Application of ASCO decreased the proportion of patients assigned to cause undermined category compared to TOAST system. Comprehensive characteristics of ASCO system might be helpful in the personalized therapy or secondary prevention for individual patients in the future.

Keywords:
TOAST, ASCO, Etiology, Minor stroke
1.
Lavallée PC, Meseguer E, Abboud H, Cabrejo L, Olivot JM, Simon O, et al. A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects.
Lancet Neurol
. 2007 Nov; 6(11): 953–60.
2.
Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, et al.; Early use of Existing Preventive Strategies for Stroke (EXPRESS) study. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison.
Lancet
. 2007 Oct; 370(9596): 1432–42.
3.
Ay H, Furie KL, Singhal A, Smith WS, Sorensen AG, Koroshetz WJ. An evidence-based causative classification system for acute ischemic stroke.
Ann Neurol
. 2005 Nov; 58(5): 688–97.
4.
Goldstein LB, Jones MR, Matchar DB, Edwards LJ, Hoff J, Chilukuri V, et al. Improving the reliability of stroke subgroup classification using the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria.
Stroke
. 2001 May; 32(5): 1091–8.
5.
Arsava EM, Helenius J, Avery R, Sorgun MH, Kim GM, Pontes-Neto OM, et al. Assessment of the predictive validity of etiologic stroke classification.
JAMA Neurol
. 2017 Apr; 74(4): 419–26.
6.
Larrue V, Berhoune N, Massabuau P, Calviere L, Raposo N, Viguier A, et al. Etiologic investigation of ischemic stroke in young adults.
Neurology
. 2011 Jun; 76(23): 1983–8.
7.
Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke
. 1993 Jan; 24(1): 35–41.
8.
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG. New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke.
Cerebrovasc Dis
. 2009; 27(5): 502–8.
9.
Landis JR, Koch GG. The measurement of observer agreement for categorical data.
Biometrics
. 1977 Mar; 33(1): 159–74.
10.
Desai JA, Abuzinadah AR, Imoukhuede O, Bernbaum ML, Modi J, Demchuk AM, et al. Etiologic classification of TIA and minor stroke by A-S-C-O and causative classification system as compared to TOAST reduces the proportion of patients categorized as cause undetermined.
Cerebrovasc Dis
. 2014; 38(2): 121–6.
11.
Marnane M, Duggan CA, Sheehan OC, Merwick A, Hannon N, Curtin D, et al. Stroke subtype classification to mechanism-specific and undetermined categories by TOAST, A-S-C-O, and causative classification system: direct comparison in the North Dublin population stroke study.
Stroke
. 2010 Aug; 41(8): 1579–86.
12.
Shang W, Liu J. Stroke subtype classification: a comparative study of ASCO and modified TOAST.
J Neurol Sci
. 2012 Mar; 314(1-2): 66–70.
13.
Gökçal E, Niftaliyev E, Asil T. Etiological classification of ischemic stroke in young patients: a comparative study of TOAST, CCS, and ASCO.
Acta Neurol Belg
. 2017 Sep; 117(3): 643–8.
14.
Wolf ME, Sauer T, Alonso A, Hennerici MG. Comparison of the new ASCO classification with the TOAST classification in a population with acute ischemic stroke.
J Neurol
. 2012 Jul; 259(7): 1284–9.
15.
Wolf ME, Grittner U, Böttcher T, Norrving B, Rolfs A, Hennerici MG; sifap1 TM investigators. Phenotypic ASCO Characterisation of Young Patients with Ischemic Stroke in the Prospective Multicentre Observational sifap1 Study.
Cerebrovasc Dis
. 2015; 40(3-4): 129–35.
16.
Amort M, Fluri F, Weisskopf F, Gensicke H, Bonati LH, Lyrer PA, et al. Etiological classifications of transient ischemic attacks: subtype classification by TOAST, CCS and ASCO—a pilot study.
Cerebrovasc Dis
. 2012; 33(6): 508–16.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.